The 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022)

Rapid MRSA and S aureus decolonization reduces prosthetic joint infections

Elvira Manzano, 20220526000000

Screening for and decolonization of Staphylococcus aureus, as well as timely use of surgical antimicrobial prophylaxis, reduces prosthetic joint infections in elderly patients with methicillin-resistant S. aureus (MRSA) undergoing hip surgery, reports an expert at ECCMID 2022.

Long COVID: What factors contribute to the risk?

Roshini Claire Anthony, 20220525180001

Only a minority of patients are considered fully recovered 1 year after being discharged from hospital due to COVID-19, with women and obese individuals at increased risk of long COVID, according to results of the prospective PHOSP-COVID* study presented at ECCMID 2022 and published in The Lancet.

Fewer hospitalizations with omicron vs delta suggest reduced severity of omicron variant

Roshini Claire Anthony, 20220523140001

Infection with the omicron variant of SARS-CoV-2 was less likely to result in hospitalization than infection with the delta variant, according to an observational study from Denmark presented at ECCMID 2022 and published in The Lancet.

Investigational drug gains upper hand over placebo in reducing CDI recurrence rates

Audrey Abella, 20220520100000

SER-109, an investigational oral microbiome therapeutic, achieves superiority over placebo in reducing recurrent Clostridioides difficile infection (CDI) rates, according to updated findings from the phase III ECOSPOR-III trial.

AZD7442 effectively TACKLEs COVID-19

Audrey Abella, 20220512100000

The phase III TACKLE trial highlights a new player in the COVID-19 treatment field – AZD7442 (tixagevimab/cilgavimab) – which demonstrated favourable efficacy and safety for nonhospitalized individuals with mild to moderate symptoms of the disease.

Remdesivir benefit greatest when given early in COVID-19

Pearl Toh, 20220511140100

Treatment with remdesivir is associated with reduced risk of hospitalization and death in non-hospitalized and hospitalized COVID-19 patients, respectively, especially when given early during the disease course, according to studies presented at ECCMID 2022.